Immunoglobulin heavy chain gene rearrangement in heavy chain deposition disease suggests it is a plasma cell disease: a case report

Qingqing Rao\textsuperscript{1,2,*}, Ricong Xu\textsuperscript{2,*} and Qijun Wan\textsuperscript{2}

Abstract
Heavy chain deposition disease (HCDD) is characterized by the deposition of truncated monoclonal immunoglobulin heavy chains along glomerular basement membranes. Truncated heavy chains are thought to be associated with plasma cell disease (PCD), but previous bone marrow cytology tests showed that only 30% of HCDD cases are related to PCDs. We report the first known use of immunoglobulin heavy chain (IGH) gene rearrangement to diagnose a patient with γ3-HCDD, although bone marrow morphology test identified no abnormalities. Our findings provide strong evidence for a correlation between PCDs and HCDD, which could help understand the genetic background underlying abnormal heavy chains and assess disease prognosis. Further, concordant with previous findings, bortezomib-based chemotherapy had a good therapeutic effect in our patient. We summarize the experience of diagnosing and treating a case of HCDD, and combine this with a literature review to further explore the correlation between PCDs and HCDD, which has important clinical value.

Keywords
Immunoglobulin heavy chain gene rearrangement test, heavy chain deposition disease (HCDD), case report, plasma cell disease, genetic background, bortezomib

Date received: 24 November 2021; accepted: 22 February 2022

\textsuperscript{*}These authors contributed equally to this work.

Corresponding author:
Qijun Wan, Department of Nephrology, First Affiliated Hospital of Shenzhen University, Sungang Road, Futian District, Shenzhen, Guangdong 518000, China.
Email: wqj2224@126.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Heavy chain deposition disease (HCDD) is a rare disorder characterized by proteinuria, hematuria, and hypertension; about 30% of patients show acute kidney injury, and HCDD accounts for 0.05%–0.33% of renal biopsy findings.1,2 Poor renal prognosis has been reported for this disease, and patients have been reported to have an overall survival of only 55 months even when using immunosuppressant treatments.3 Bridoux and colleagues found that during HCDD development, the truncated CH1 domain of the free heavy chain cannot bind to the light chain, and that its high tissue affinity leads to kidney injury upon deposition along the glomerular basement membrane.4–6 However, it is still unclear how truncated heavy chains are produced.

We encountered a patient with HCDD and potential plasma cell disease (PCD) in whom we undertook hematological examinations to show that immunoglobulin heavy chain (IGH) gene rearrangement may explain the cause of abnormal heavy chains from a molecular biological perspective. This finding could be beneficial in fully assessing the disease and its prognosis.

Case presentation

The 62-year-old female patient was admitted to our hospital for edema of both lower limbs and foamy urine for 3 weeks. She had a history of hypertension for 1 year. On admission, her blood pressure was 148/86 mmHg, and moderate symmetrical sunken edema of the lower limbs was evident. Blood biochemical and imaging findings are shown in Table 1.

Figure 1 shows a pathological map of our patient’s kidney biopsy. Nodular sclerosis was found upon optical microscopy. Electron microscopy revealed a ‘line-like’ deposition of dot-like and powder-like electron dense matter along the glomerular basement membrane and tubular basement membrane, suggestive of HCDD. We performed a paraffin repair and IGH retaining assay, and the final diagnosis was γ3-HCDD.

Bone marrow puncture and bone marrow biopsy revealed no abnormalities. However, serum and urine free light chain levels were elevated. To further clarify the correlation between HCDD and abnormal lymphoproliferative disease, we used the IGH gene rearrangement assay. This was positive for IGH, IGK, and IGL-related genes, suggesting the existence of a potential B lymphocyte tumor.

Our patient received eight cycles of bortezomib-based chemotherapy. Her lower extremity edema disappeared during the second month of an 8-month follow-up, proteinuria reduced from 2.56 g/24 hours to 0.3 g/24 hours, serum and urine free light chain κ and λ decreased to near normal levels (serum κ, 18.58 mg/L; serum λ, 9.71 mg/L; urine λ, 2.68 mg/L; and urine κ, 18.46 mg/L), serum albumin increased to normal levels, and stable renal function was observed. She has also only needed assessment as an outpatient.

Written informed consent was obtained from the patient and her family for her anonymized data to be published in this article. The reporting of this study conforms with CARE guidelines.7

Discussion

HCDD is accompanied by abnormal plasma cell hyperplasia in 30% of cases,8 and bortezomib-based chemotherapy, a first-line drug for multiple myeloma, has been reported to show excellent efficacy for many HCDD patients. Accordingly, HCDD is often thought to be a PCD; however, for the remaining 70% of HCDD patients without abnormal plasma cell hyperplasia, it remains unclear how truncated heavy chains are produced and
whether bortezomib chemotherapy is a suitable treatment.

*IGH* genes comprise a recombination of V, D, and J genes, which can exist in a broad array of combinations. Malignant tumor cells have a common clone of origin, but normal B cells contain a unique length of the *IgH* variable region. Thus, evaluations of the clonal nature of tissue samples contribute to the diagnosis of B lymphoma tumors. *IGH* gene rearrangement tests use PCR to detect the monoclonality of *IG* genes in B lymphoma with a detection limit of 1%. Plasma cell tumors are characterized by monoclonal abnormal multiplication, and have the same rearranged gene fragments, so specific bands are detected after amplification.

### Table 1. Biochemical, imaging, and genetic examination results for our patient on admission.

| Parameter | Patient value | Normal reference range |
|-----------|---------------|------------------------|
| White blood cells \((\times 10^9/L)\) | 6.05 | 3.5–9.5 |
| Platelets \((\times 10^9/L)\) | 159 | 125–350 |
| Hemoglobin \((g/L)\) | 105 | 115–150 |
| Urine protein | 2+ | Negative |
| Urine red blood cell count \((10^4/mL)\) | 30000 | <8000 |
| Normal urine red blood cell | 60% | |
| 24-hour urine total protein \((mg)\) | 2568† | 0–150 |
| /2-microglobulin/blood | 1.5† | 0.8–1.8 |
| Urine free light chain \(\kappa\) \((mg/L)\) | 117† | 0.39–15.10 |
| Urine free light chain \(\lambda\) \((mg/L)\) | 13† | 0.81–10.10 |
| Urine free light chain \(\kappa/\lambda\) | 9† | 0.461–4.00 |
| Blood free light chain \(\kappa\) \((mg/L)\) | 27.8† | 3.30–19.40 |
| Blood free light chain \(\lambda\) \((mg/L)\) | 38.8† | 5.71–26.30 |
| Blood free light chain \(\kappa/\lambda\) | 0.7165 | 0.26–1.65 |
| Complement C3 \((g/L)\) | 0.67† | 0.9–1.8 |
| Complement C4 \((g/L)\) | 0.080† | 0.1–0.4 |
| Serum creatinine \((\mu mol/L)\) | 67.0 | 46–92 |
| Albumin \((g/L)\) | 34.5 | 40–55 |
| Thyroid function \((T3, T4, TSH, TT3, and TT4)\) | normal | normal |
| Autoimmune test \((anti-ANA and anti-ENA)\) | normal | normal |
| Cancer biomarkers \((CEA, AFP, CA125, CA199, and CA153)\) | normal | normal |
| Pathology of abdominal fat biopsy | negative | negative |
| Blood and urine immunofixation electrophoresis | negative | negative |
| Systemic lymph node scan | negative | negative |
| Bone marrow puncture and biopsy | negative | negative |
| Bone scanning | negative | negative |
| Bone marrow flow cytometry | negative | negative |
| *IgH* gene rearrangement | *IGH*(+), *IGK*(+), *IGL*(+), *IGH*(DH-JH) (-) | – |

T3, triiodothyronine; T4, thyroxine; TSH, thyroid stimulating hormone; TT3, total triiodothyronine; TT4, total thyroxine; ANA, antinuclear antibodies; ENA, extractable nuclear antigens; CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA, cancer antigen.

†, higher than the normal reference range; ‡, lower than the normal reference range.
Thus, *IGH* gene rearrangements can be helpful in distinguishing tumoral hyperplasia from lymphoid tissue reactive hyperplasia.\(^{12}\)

In B lymphoma tumors, the positivity rates of detection are 90% for both *IGH* and *IGK*, and the positivity rate of combined detection is greater than 95%. *IGH* (DH-JH) assessment detects the incomplete rearrangement of *IGH*, and *IGL* detection complements and validates the *IGK*
Hence, *IGH* gene rearrangement can improve the early diagnosis of lymphoma from the level of cytology directly to the molecular level with a positivity rate of 83.3%. This technology has previously been applied to the diagnosis and prognosis of lymphoma and myeloma, but to our knowledge has never been used in patients with HCDD.

Considering the high sensitivity of *IGH* gene rearrangements and to further clarify the correlation between HCDD and PCDs, we used this technique for our patient. *IGH*, *IGK*, and *IGL*-related genes were positive, suggesting the existence of potential PCDs. This is the first known report showing *IGH* gene rearrangement in a patient with HCDD. Our results suggest that HCDD is a potential PCD, although normal bone marrow aspiration and flow cytometry were observed.

Hematopoietic stem cell transplantation, methylprednisolone, cyclophosphamide, and melpharone-based chemotherapy have previously been the main treatments for HCDD. In 2014, the application of bortezomib for patients with HCDD was first reported, and this showed good efficacy. Bortezomib is a proteasome inhibitor that inhibits the degradation of ubiquitinated proteins, destabilizes the internal environment, and leads to cell death. It has been used as a first-line drug for multiple myeloma since 2008. A multi-center study showed that patients with HCDD receiving bortezomib-based chemotherapy had an improved average kidney survival time of more than 85 months compared with immunosuppressive therapy which had a median survival of 55 months.

Bortezomib-based chemotherapy also had a good therapeutic effect in our patient. The good clinical outcomes for myeloma treatment with bortezomib, resulting in abnormal plasma cell death, support our hypothesis that genetic abnormalities of *IGH*, *IGK*, and *IGL* genes lead to the production of abnormal heavy chains, but further studies are needed to confirm this.

In summary, our findings from *IGH* gene rearrangement testing offers a higher sensitivity for HCDD than bone marrow morphology tests alone. Our findings from this testing of our current patient indicate that HCDD is a plasma cell disease. Moreover, *IGH* gene rearrangement testing can reveal the genetic background of the truncated heavy chain in patients with HCDD, so we recommend its use in such cases. Bortezomib-based chemotherapy should also be considered for patients with HCDD to achieve a good clinical response.

**Declaration of conflicting interest**
The authors declare that there is no conflict of interest.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This work was supported by grants from the Shenzhen Key Medical Discipline Construction Fund (Project number: SZXK009); Sanming Project of Medicine in Shenzhen (Project number: SZSM201512004); National Natural Science Foundation of China (Project number: 81900639); and Research Program of the Shenzhen Science and Technology Project number: R&D Fund (Project number: JCYJ20190806162807125).

**ORCID iD**
Qijun Wan https://orcid.org/0000-0002-1304-1333

**Supplemental material**
Supplemental material for this article is available online.

**References**
1. Ronco P, Plaisier E, Mougnot B, et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to
pathophysiology-driven therapy. *Clin J Am Soc Nephrol* 2006; 1: 1342–1350.

2. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. *Clin J Am Soc Nephrol* 2012; 7: 231–239.

3. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. *J Am Soc Nephrol*. 2001; 12: 1482–1492.

4. Bender S, Ayala MV, Javaugue V, et al. Comprehensive molecular characterization of a heavy chain deposition disease case. *Haematologica* 2018; 103: e557–e560.

5. Bonaud A, Bender S, Touchard G, et al. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. *Blood* 2015; 126: 757–765.

6. Bridoux F, Javaugue V, Bender S, et al. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. *Kidney Int* 2017; 91: 423–434.

7. Gagnier JJ, Kienle G, Altman DG, et al.; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. *Headache* 2013; 53: 1541–1547.

8. Kourelis TV, Nasr SH, Dispenzieri A, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *Am J Hematol* 2016; 91: 1123–1128.

9. Maezawa M, Watanabe KI, Horiuchi N, et al. Molecular diagnosis of bovine B-cell lymphoma using polymerase chain reaction for immunoglobulin heavy chain gene. *J Vet Med Sci* 2020; 82: 61–63.

10. Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. *Leukemia* 2012; 26: 2159–2171.

11. Ohlin M, Scheepers C, Corcoran M, et al. Inferred allelic variants of immunoglobulin receptor genes: a system for their evaluation, documentation, and naming. *Front Immunol* 2019; 10: 435.

12. Mendoza H, Tormey CA, Rinder HM, et al. The utility and limitations of B- and T-cell gene rearrangement studies in evaluating lymphoproliferative disorders. *Pathology* 2021; 53: 157–165.

13. Kros JM, Bagdi EK, Zheng P, et al. Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma. *J Neurosurg* 2002; 97: 1390–1396.

14. Van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia* 2003; 17: 2257–2317.

15. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. *Leukemia* 2013; 27: 423–429.

16. Patel K, Dillon JJ, Leung N, et al. Use of bortezomib in heavy-chain deposition disease: a report of 3 cases. *Am J Kidney Dis* 2014; 64: 123–127.

17. Cohen C, Royer B, Javaugue V, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. *Kidney Int* 2015; 88: 1135–1143.